Podcasts about Adjuvant

In July 2023, the ACOG released a Practice Advisory stating, “Based on data on the benefit of adjunct HPV vaccination, ACOG recommends adherence to the current Centers for Disease Control and Prevention (CDC) recommendations for vaccinations of individuals aged 9–26 years, and to consider adjuvant HPV vaccination for immunocompetent previously unvaccinated people aged 27–45 years who are undergoing treatment for CIN 2+”. The possible beneficial effect of peri-treatment HPV vaccination goes back to the early 2010s. But science is always changing, and MEDICINE MOVES FAST. In September 2025, the Lancet's Obstetrics, Gynecology, and Women's Health journal published the VACCIN trial to test that guidance. These authors found that, “Although previous studies, including meta-analyses and observational studies, have shown that adjuvant HPV vaccination reduces the recurrence of cervical dysplasia after surgical treatment, our trial suggests that adjuvant HPV vaccination is not effective in reducing the recurrence of CIN 2–3 lesions, contradicting the conclusions of previous works”. They have also called for a REVISION to prior guidance. This is FASCINATING. Listen in for details. 1. ACOG PA July 2023, “Adjuvant Human Papillomavirus Vaccination for Patients Undergoing Treatment for Cervical Intraepithelial Neoplasia 2+”2. Adjuvant prophylactic human papillomavirus vaccination for prevention of recurrent high-grade cervical intraepithelial neoplasia lesions in women undergoing lesion surgical treatment (VACCIN): a multicentre, phase 4 randomised placebo-controlled trial in the Netherlands: https://www.sciencedirect.com/science/article/pii/S305050382500007X#:~:text=To%20our%20knowledge%2C%20this%20is,the%20conclusions%20of%20previous%20works.STRONG COFFEE PROMO: 20% Off Strong Coffee Company https://strongcoffeecompany.com/discount/CHAPANOSPINOBG

Join Jenny Gilchrist, Breast Oncology Nurse Practitioner at Macquarie University Hospital in Sydney, and Suzanne Frank, an Advanced Specialist Breast Cancer Pharmacist at The Christie NHS Foundation Trust in Manchester, UK as they delve into practical service redesign and ePROMS implementation in the adjuvant breast cancer clinic setting, sharing insights that can empower Australian Nurses to drive innovation and patient-centred care—even amidst challenging capacity and medicine rollout scenarios.

Please visit answersincme.com/860/TSG to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses evidence-based insights that inform the practical integration of adjuvant immunotherapy regimens into cutaneous squamous cell carcinoma (CSCC) care, based on available clinical data. Upon completion of this activity, participants should be better able to: Review the rationale for immunotherapy in the adjuvant treatment of patients with high-risk resected cutaneous squamous cell carcinoma (CSCC); Summarize the latest clinical trial data evaluating adjuvant immunotherapy in high-risk CSCC; and Outline evidence-based, multidisciplinary strategies to optimize the care of patients with high-risk CSCC in the adjuvant setting.

At the latest ASCO-2025 meeting, Dr. Chris Booth shared the results of a study showing that adjuvant structured exercise improves overall survival in colon cancer. He joins Healthcare Unfiltered EXPRESS to detail the study, its findings, and what is next. Please share and join the conversation.

Featuring an interview with Dr Shannon N Westin, including the following topics: Biomarker testing and utility in ovarian cancer (OC) (0:00) Selection of a PARP inhibitor for the treatment of OC (9:18) Addition of immunotherapy to up-front treatment of OC (15:50) Utility of minimal residual disease and circulating tumor DNA assays in OC (17:10) Selection of treatment for recurrent OC (21:46) Clinical decision-making involved with PARP inhibitors for endometrial cancer (EC) (28:22) Adjuvant therapy for EC (32:28) Utility of lenvatinib/pembrolizumab in EC (35:08) Clinical findings supporting the potential use of selinexor for EC (39:42) Key findings involving trastuzumab deruxtecan (T-DXd) for HER2-positive gynecologic cancers (43:22) Management of adverse effects associated with T-DXd (49:49) CME information and select publications

Refresh your knowledge of testis cancer with this punchy pod with testis cancer gurus, Prof Christian Kollmannsberger (Vancouver Cancer Centre, Vancouver), and Prof Ben Tran (Peter MacCallum Cancer Centre, Melbourne). We pick their brains on three topical areas in testis cancer;1. Adjuvant chemo - balancing early gains vs late effects. How can we figure out who benefits?2. Primary RPLND - does robotic surgery change the value proposition of surgery vs chemotherapy? 3. The outstanding mi371 tumour marker - a bluffer's guideWith your usual hosts. Declan Murphy and Renu Eapen. Even better on our YouTube channel

Josh and Michael return to their normal scheduled broadcast, continuing their never-ending Back to Basics series. In this episode, they discuss several interesting developments in the adjuvant management of urothelial cancer, focussing on the sometimes contradictory data of adjuvant immunotherapy. This is an emerging area of treatment that you will not want to miss!Studies discussed in this episodeAMBASSADORCheckmate 274IMvigor010For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Monty Pal discusses more correlates from this trial including matched baseline and progression tissue samples.

Frische Eindrücke aus Chicago: Harald Müller-Huesmann und Peter Meyerhuber sprechen über internationale Stimmungslagen, aktuelle Studiendaten – u.a. zur ATOMIC-Studie – und die Rolle künstlicher Intelligenz in der Onkologie.

Show notes at pharmacyjoe.com/episode1024. In this episode, I'll discuss the use of adjuvant midodrine in patients with septic shock. The post 1024: Adjuvant Midodrine Lowers Norepinephrine Dose But Not Length of Stay in Patients With Septic Shock appeared first on Pharmacy Joe.

AABP Executive Director Dr. Fred Gingrich is joined by Dr. Chris Chase, Emeritus Professor in the Department of Veterinary and Biomedical Sciences and Dr. Curt Vlietstra, Senior Professional Services Veterinarian with Boehringer Ingelheim. This episode is sponsored by Boehringer Ingelheim, manufacturer of the Pyramid line of cattle vaccines. Find more information about Pyramid/Presponse vaccines by visiting this page.  Adjuvants are a critical component of vaccines, but they can be an overlooked factor when putting together a vaccine program. The three roles of adjuvants serve in vaccines are creating a danger signal for the host, help the immune system recognize the antigen and to protect the antigen.  Historically, there has been some skepticism around vaccinating young calves early due to the presence of maternal antibodies. Our guests discuss what role vaccines serve in a calf program while recognizing the importance of colostral immunity and the purpose it serves. Adjuvants can serve an important role in young calves to help with a vaccine-induced immune response. Our guests discuss the METASTIM adjuvant, how it differs from other adjuvants, and the role it plays in boosting immunity even in the face of maternal antibodies.  Veterinarians play a critical role in developing vaccine programs for their clients' herds. This not only includes ensuring that the appropriate vaccines are selected for the herd, but also making sure that nutrition, specifically vitamin and mineral nutrition, is appropriate, stress is minimized, and vaccine storage and administration is correct. We close the podcast by discussing the future of vaccine and adjuvant technologies that veterinarians should be aware of and how these potential uses can improve cattle health. Veterinarians can go to https://bi-animalhealth.com/cattle/ or talk to their Boehringer Professional Services Veterinarian for more information.

Learn how your treatment plan is decided and terms you may seeWe continue our series to help you understand cancer and its treatment. This week we focus on surgery, the oldest form of cancer treatment. Learn about surgery timing, types of cancer surgery, and how NCCN evidence-based guidelines provide a standard treatment path no matter where you are.In this Episode:02:58 - Wisconsin-Cheese, UFOs, and Booyah Stew04:52 - Anna Quindlen: Get a Life Where You Are Generous"08:06 - Medical Specialists Involved in Cancer Care08:52 - Treatment Decisions, Tumor Board and NCCN Guidelines12:03 - Adjuvant and Neoadjuvant Therapy13:13 - Surgery Timing, Reasons and Types18:00 - Discussion - NCCN and Role of Research24:34 - Reeves Keyworth:“On Loved Ones Telling the Dying to ‘Let Go”23:54 - OutroSurgery, radiation therapy, and chemotherapy alone or in combination are the most-common methods used to treat cancer. Specific treatment varies depending on the kind of cancer, the extent of the disease, its rate of progression, and the condition of the person. Surgery alone may not result in a cure and often chemotherapy and/or radiation are needed after surgery. Learn all about surgery and the guidelines your doctor will be following for your treatment.Support the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DEJ865. CME/MOC/CC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.Intelligently Achieving the Potential of Adjuvant CDK4/6 Inhibition in Reducing Risk of Recurrence While Maintaining QOL in HR+, HER2- EBC: An AI-Driven Educational Resource for Improving MDT Collaboration and Patient-Clinician Communication In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DEJ865. CME/MOC/CC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.Intelligently Achieving the Potential of Adjuvant CDK4/6 Inhibition in Reducing Risk of Recurrence While Maintaining QOL in HR+, HER2- EBC: An AI-Driven Educational Resource for Improving MDT Collaboration and Patient-Clinician Communication In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DEJ865. CME/MOC/CC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.Intelligently Achieving the Potential of Adjuvant CDK4/6 Inhibition in Reducing Risk of Recurrence While Maintaining QOL in HR+, HER2- EBC: An AI-Driven Educational Resource for Improving MDT Collaboration and Patient-Clinician Communication In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DEJ865. CME/MOC/CC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.Intelligently Achieving the Potential of Adjuvant CDK4/6 Inhibition in Reducing Risk of Recurrence While Maintaining QOL in HR+, HER2- EBC: An AI-Driven Educational Resource for Improving MDT Collaboration and Patient-Clinician Communication In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

How do the eligibility criteria for the monarchE and NATALEE clinical trials compare? Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002403?ecd=bdc_podcast_libsyn_mscpedu

Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease recurrence, as well as the rapid enrollment of this innovative study and what it means for the future of kidney cancer treatment. Read the publication in Nature. https://www.nature.com/articles/s41586-024-08507-5 Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

No description available

TWiV reviews passing of Ann Palmenberg, deadly illness in western Congo, US disruption of mpox and ebolavirus programs, first measles death in Texas outbreak, flu vaccine selection meeting postponed, US withdraws from polio, malaria, HIV programs and more, clade 2.3.4.4b H5N1 viruses have a long HA stalk, and systems vaccinology to identify predictors of durable antibody response to multiple vaccines in humans. Hosts: Vincent Racaniello, Alan Dove, Rich Condit, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV ASV 2025 Ann Palmenberg dies (Cress) Ann at Chumakov Symposium (YouTube) Unknown illness in Congo (NY Times) Bad news about mpox outbreak (NPR) US interrupts Ebola prevention program (NPR) First measles death in Texas (Texas Trib) Flu vaccine selection meeting canceled (NY Times) US ends funding for polio, HIV, malaria and more (NY Times) Clade 2.3.4.4b H5N1 neuraminidase has a long stalk (mBio) Predictors of durable antibody responses to vaccines (Nat Immunol) Review of adjuvants (Vaccinol Methods Vacc Res) Timestamps by Jolene Ramsey. Thanks! Weekly Picks Brianne – Video of the Northern Lights from Space Rich – Vaccination for Sudan Ebola virus disease Alan – Specialized moth wing scales give it 3-D camouflage (news and paper) Vincent – WHO Recommendations for Influenza Vaccine Composition for the 2025-2026 Northern Hemisphere Influenza Season Listener Picks Gerry – Eukaryotic Transcription Anne – The science of the solar system Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

In this episode, Jame Abraham, MD, FACP; William J. Gradishar, MD, FACP, FASCO; and Laura Spring, MD, review key insights and frequently asked questions related to the CDK4/6 inhibitors used to treat patients with early and metastatic hormone receptor (HR)–positive/HER2-negative breast cancer from a live program held in January 2025. Key clinical pearls include:Adjuvant treatment selection recommendations for patients with HR-positive/HER2-negative early breast cancer based on disease and patient characteristics as well as the latest data and guidelines presented by Dr. GradisharTherapeutic strategies for patients diagnosed with HR-positive/HER2-negative metastatic breast cancer (MBC) presented by Dr. AbrahamAddressing challenges related to CDK4/6 inhibitor adherence and adverse event mitigation presented by Dr. SpringPresenters:Jame Abraham, MD, FACPEnterprise Chair and Professor of MedicineDepartment of Hematology and Medical OncologyCleveland ClinicCleveland, OhioWilliam J. Gradishar, MD, FACP, FASCOBetsy Bramsen Professor of Breast OncologyRobert H. Lurie Comprehensive Cancer CenterNorthwestern UniversityChicago, IllinoisLaura Spring, MDBreast Medical OncologistMass General Hospital Cancer CenterHarvard Medical SchoolBoston, MassachusettsLink to full program including downloadable slides and on-demand webcasts: https://bit.ly/4b5GFqqTo claim credit for listening to this episode, please visit the podcast online at the link above.

Featuring perspectives from Dr Enriqueta Felip and Dr Helena Yu, including the following topics: Introduction (0:00) First-Line Treatment of Metastatic Disease (2:34) Adjuvant and Neoadjuvant Therapy (22:31) EGFR Exon 20 Insertion Mutations (34:21) Antibody-Drug Conjugates (42:45) CME information and select publications

In our exclusive interview, Dr Cohen provided insights into the evolving role of circulating tumor DNA (ctDNA) in clinical decision-making for patients with colorectal cancer (CRC), particularly through findings from the CIRCULATE-Japan GALAXY trial (UMIN000039205). She highlighted how ctDNA has emerged as a strong prognostic factor for recurrence risk in CRC and explored its potential to guide therapy escalation or de-escalation. She also discussed the heterogeneity in the patient population included in the CIRCULATE-Japan GALAXY study and how ctDNA negativity correlates with improved disease-free and overall survival. Additionally, Dr Cohen outlined what data are still needed to integrate ctDNA testing into routine clinical practice and how sustained vs transient ctDNA clearance may influence treatment and surveillance strategies moving forward.

In this episode, we're taking you behind the scenes into the fascinating world of fertility science with Natalie Moska, Laboratory Manager at Genea Fertility Perth. With over 16 years of experience across WA and the UK, Natalie shares her wealth of knowledge on the cutting-edge therapies helping patients on their fertility journey.  We break down key adjuvant treatments like:  PICSI – what is it, and who benefits?  Zymot– how does it work for sperm selection?  Calcium Ionophore Activation – the role it plays in fertilisation.  Plus, Natalie opens up about her passion for embryology, her favourite part of the job, and what keeps her inspired in the lab. Whether you're deep in treatment or simply curious, this episode is packed with insights to help you understand the science behind fertility.  Proudly supported by Genea Fertility

HER2 Breast Cancer is complicated, and this week, we explore those with residual disease post neoadjuvant therapy (KATHERINE) and the idea of de-escalation in a subpopulation of HER2-positive breast cancer patients (PERSEPHONE). The advent of a new class of drugs leads to excitement, unanswered questions and boundless opportunities. With ADC (antibody-drug conjugates) making their mark on traditional chemotherapy, the landscape of everything we treat is slowly changing. Studies discussed in the episode:KATHERINEPERSEPHONEFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do. Hosted on Acast. See acast.com/privacy for more information.

In this episode of SurgOnc Today®, Dr. Julie Hallet, Chair of the HPB Disease Site Work Group, and Dr. Patricio Polanco, Vice-Chair of the HPB Disease Site Work Group, are joined by Drs. Sajid Khan from Yale School of Medicine and Dr. Cecilia Ethun from UT Southwestern. They will wrap the 2024 HPB year by reviewing the top HPB surgical oncology published this year.  References/Resources: #10: AMPLIFY https://www.nature.com/articles/s41591-023-02760-3   #9: Adjuvant therapy for IPMN-derived PDAC - https://ascopubs.org/doi/abs/10.1200/JCO.23.02313   #8: HELIX https://jamanetwork.com/journals/jama/fullarticle/2822555  #7: CAMINO  https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00572-7/fulltext  #5 : PANDAS/PRODIGE https://www.annalsofoncology.org/article/S0923-7534(24)03884-5/fulltext

Early Breast Cancer had one of its defining moments in the 1990s, when five years of adjuvant tamoxifen reduced the recurrence risk of invasive breast cancer by 49%! These days, those types of improvements are much harder to substantiate with the effect treatments currently on the market, but there is promise. This week, on our Back to Basics episode, Michael and Josh look at the role of abemaciclib and ribociclib in the adjuvant setting in patients with high-risk early breast cancer. Both of these drugs are CDK4/6 inhibitors and have been shows to be efficacious in the metastatic hormone receptor positive status breast cancer space.This week we explore MONARCH-E and NATALEE and highlight the data and how it could impact CKD's role in this emerging landscape.Studies discussed in the episode:MONARCH-ENATALEEFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do. Hosted on Acast. See acast.com/privacy for more information.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain welcome Dr. Martina Murphy, an Associate Professor of Medicine and Senior Associate Dean of Graduate Medical Education at the University of Florida, to discuss the current landscape of ovarian cancer. Join us as we dive into the critical aspects of diagnosing and managing ovarian cancer, including: •⁠  ⁠The importance of surgical staging and primary debulking surgery •⁠  ⁠The role of genetic testing, including BRCA and NGS, in treatment planning •⁠  ⁠Adjuvant therapy options, focusing on platinum-based chemotherapy and the use of Bevacizumab •⁠  ⁠Insights into PARP inhibitors and their application in BRCA-positive and wild-type patients •⁠  ⁠Navigating treatment options for relapsed and refractory ovarian cancer, including the use of antibody-drug conjugates like Mirvetuximab and Trastuzumab Deruxtecan (TDXd). Dr. Murphy shares her expertise on the latest advancements in ovarian cancer treatment, the significance of genetic testing, and the management of side effects associated with various therapies. Tune in for a comprehensive overview of the standard of care for ovarian cancer and the evolving treatment landscape. Don't forget to check out our other episodes for more discussions on practice-changing data and current treatment options in oncology! Subscribe to the Oncology Brothers podcast for more insights and updates in the field of oncology! Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MZG865. CME/MOC/AAPA/IPCE credit will be available until November 9, 2025.Reinforcing Precision Tactics in Genomically Altered Resectable NSCLC: Collaborative Workflows and Personalized Solutions for Integration of Adjuvant EGFR- and ALK-Targeted Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MZG865. CME/MOC/AAPA/IPCE credit will be available until November 9, 2025.Reinforcing Precision Tactics in Genomically Altered Resectable NSCLC: Collaborative Workflows and Personalized Solutions for Integration of Adjuvant EGFR- and ALK-Targeted Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MZG865. CME/MOC/AAPA/IPCE credit will be available until November 9, 2025.Reinforcing Precision Tactics in Genomically Altered Resectable NSCLC: Collaborative Workflows and Personalized Solutions for Integration of Adjuvant EGFR- and ALK-Targeted Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MZG865. CME/MOC/AAPA/IPCE credit will be available until November 9, 2025.Reinforcing Precision Tactics in Genomically Altered Resectable NSCLC: Collaborative Workflows and Personalized Solutions for Integration of Adjuvant EGFR- and ALK-Targeted Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

Dr. Rick Greene discusses with Dr. Dana Dominguez the association of adjuvant chemoradiation in resected biliary cancer with improved overall survival compared to chemotherapy alone, as reported in her article, "Adjuvant Chemoradiation in Resected Biliary Adenocarcinoma: Evaluation of SWOG S0809 with a Large National Database.” Article: Adjuvant Chemoradiation in Resected Biliary Adenocarcinoma: Evaluation of SWOG S0809 with a Large National Database | Annals of Surgical Oncology (springer.com)

Do you know the best approaches to managing patients with endometrial cancer in the adjuvant setting?   Credit available for this activity expires: 9/24/2025 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001649?ecd=bdc_podcast_libsyn_mscpedu

Please visit answersincme.com/RKX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in skin cancer discusses strategies for adjuvant immunotherapy in resectable melanoma. Upon completion of this activity, participants should be better able to: Review the guideline-recommended role of adjuvant immunotherapy for the treatment of resectable melanoma; Describe the key adverse events associated with adjuvant immunotherapy for the treatment of resectable melanoma; Outline evidence-based, patient centric strategies to optimize the benefit-to-risk impact of adjuvant immunotherapy in resectable melanoma care

October 2024 Journal Club Podcast Title: Extended Long-Term Outcome After Conservative Decompressive Microsurgery and Routine Adjuvant Fractionated Stereotactic Radiotherapy for Symptomatic Cavernous Sinus Meningiomas To read journal article: https://journals.lww.com/neurosurgery/fulltext/2024/10000/extended_long_term_outcome_after_conservative.14.aspx Authors: Joachim Krauss and Manolis Polemikos Guest faculty: Jacques Morcos Moderator: Jeffrey Traylor Committee Co-chair: Rafael Vega

Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.

The fourth episode in the HRT after breast cancer series features Dr. Louise Newson, who has faced criticism for her willingness to prescribe HRT to breast cancer patients. At the same time, she has been described as a lifesaver by many of the women she treats.Dr. Louise Newson is a GP who has transformed the landscape for menopausal women worldwide. She became a member of the Royal College of Physicians in 1998 and a Fellow of the Royal College of GPs in 2016. She is also a menopause specialist and a member of the UK Government's Menopause Taskforce.This mini-series explores hormone replacement therapy (HRT) after breast cancer, a controversial and emotive subject. The conversation focuses on the further understanding of risks and benefits of HRT (hormone replacement therapy) or also MHT (menopause hormone therapy), the emotional impact on patients, and the different views among medical professionals. The goal is to provide understanding for patients seeking HRT after breast cancer and insight for doctors on how to move forward without robust evidence. Dani Binnington, host of the Menopause And Cancer podcast, and founder of the not-for-profit organisation Menopause And Cancer has spoken to hundreds of women who feel like they are in a void and have nowhere to turn to in discussing this difficult topic. Welcome to our HRT after breast cancer series.In this episode we discuss:Dr. Newson's passion for empowering women to navigate the menopause How it felt when Dr. Newson prescribed HRT to a breast cancer patient for the first timeThe role of shared-decision making Holding uncertainty between the doctor and the patientEmpowering women to make informed decisions about their health is crucial in improving their quality of lifeEpisode Highlights:00:00 Intro.03:09 Challenges of hormone replacement therapy after cancer.06:38 Doctor offers hormonal treatment to patient post-surgery.12:00 Alternative options suggested for women's health without HRT.20:45 Adjuvant treatment side effects and drug holidays.23:40 Discussing oestrogen management for cancer survivors post-menopause.30:28 Lack of research on women's health risks.44:04 Advocate for women's health and research needs.47:03 Effective communication between patients and doctors crucial.Connect with us:For more information and resources visit our website: www.menopauseandcancer.org Or follow us on Instagram @menopause_and_cancer Join our Facebook group: www.facebook.com/groups/menopauseandcancerchathubThe walking challenge I mention is here for you: https://move-with-menopause-and-cancer.raiselysite.com/

Lots of recent updates to cover this week... 1. Adjuvant pembrolizumab of RCC demonstrates OS improvement in NEJM publication (DOI: 10.1056/NEJMoa2312695) 2. Yet adjuvant nivolumab did not demonstrate OS improvement in the adjuvant setting. There may be a few reasons for this (https://doi.org/10.1200/JCO.2024.42.4_suppl.LBA358) 3. A cytokine-fusion protein, nogapendekin alfa inbakicept, is approved for intravesicular use in BCG-unresponsive bladder cancer. This agent appears to activity in NSCLC too... 4. The Phase II APPLE trial provides some evidence than deferring osimertinib to the second-line setting in metastatic EGFR-mutated NSCLC may yield similar OS to first-line use of osimertinib. (https://doi.org/10.1200/JCO.23.01521) 5.The METALLICA study provides a nice roadmap for empiric metformin use when starting alpelisib (https://doi.org/10.1016/j.eclinm.2024.102520) 6. Does CPX-351 cause less intestinal damage than 7 + 3? And could that explain the discordance between time of neutropenia and infection rates? A mouse model suggests yes. (https://doi.org/10.1200/jco.2017.77.6112)

Recent research reveals just how effectively probiotics improve inflammation, cognition, and depression. Tune in to hear the details of the latest in health science. Watch/Read Next… Can You Use Probiotics for Brain Health: https://drruscio.com/probiotics-for-brain-health/  What are the Signs You Need Probiotics? https://drruscio.com/what-are-the-signs-you-need-probiotics/  The Best Probiotics Protocol? The Triple Therapy Approach: https://drruscio.com/triple-therapy-probiotic-protocol/  The Best Probiotics for Anxiety & How to Use Them: https://drruscio.com/best-probiotic-for-anxiety/  Depression is More Than Serotonin. So What is it? https://drruscio.com/serotonin-theory-of-depression/  How to Improve Depression & Anxiety Without Medication: https://drruscio.com/natural-mood-enhancers/  Leaky Gut Supplements to Target Inflammation:  ​https://drruscio.com/leakygut-supplements/  Reduce Stress Inflammation in 5 Steps: https://drruscio.com/reduce-stress-inflammation/  How to Reduce Brain Inflammation: 4 Actions You Can Take Today: https://drruscio.com/reduce-brain-inflammation/    Timestamps 00:00 Intro  00:42 How to Determine Evidence Quality 02:52 The Science Behind Depression is Evolving 05:52 “Microbiota Diversity as a New Target to Improve Mood” 08:05 The Effect of Probiotics & Fiber in Cognitive Function  10:50 Probiotics for Premature Infant Neurodevelopment  13:12 Probiotics for Alcohol Use Disorder  14:40 Probiotics for Inflammation 17:48 Probiotics for MS  19:22 “Probiotic Effects on Sexual Function in Depressant Women” Featured Studies  Microbiota Diversity and Inflammation as a New Target to Improve Mood: Probiotic Use in Depressive Disorder: https://pubmed.ncbi.nlm.nih.gov/37800206/  The effect and safety of probiotics on depression: a systematic review and meta-analysis of randomized controlled trials: https://pubmed.ncbi.nlm.nih.gov/37247076/  Effect of Continuous Ingestion of Bifidobacteria and Dietary Fiber on Improvement in Cognitive Function: A Randomized, Double-Blind, Placebo-Controlled Trial: https://pubmed.ncbi.nlm.nih.gov/37836458/  Probiotic supplements are effective in people with cognitive impairment: a meta-analysis of randomized controlled trials: https://pubmed.ncbi.nlm.nih.gov/36629438/  Effectiveness of a probiotic combination on the neurodevelopment of the very premature infant: https://pubmed.ncbi.nlm.nih.gov/37365274/  The Beneficial Effects of Lactobacillus GG Therapy on Liver and Drinking Assessments in Patients with Moderate Alcohol-Associated Hepatitis: https://pubmed.ncbi.nlm.nih.gov/37040544/  The role of probiotic supplementation in inflammatory biomarkers in adults: an umbrella meta-analysis of randomized controlled trials: https://pubmed.ncbi.nlm.nih.gov/37698776/  The effect of probiotic supplementation on the clinical and para-clinical findings of multiple sclerosis: a randomized clinical trial: https://pubmed.ncbi.nlm.nih.gov/37903945/  Effects of Microecological Regulators on Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials: https://pubmed.ncbi.nlm.nih.gov/36904103/  Adjuvant administration of probiotic effects on sexual function in depressant women undergoing SSRIs treatment: a double-blinded randomized controlled trial: https://pubmed.ncbi.nlm.nih.gov/38216917/   Get the Latest Updates Facebook - https://www.facebook.com/DrRusciodc Instagram - https://www.instagram.com/drrusciodc/ Pinterest - https://www.pinterest.com/drmichaelrusciodc    DISCLAIMER: The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified healthcare provider before starting any new treatment or discontinuing an existing treatment. Music featured in this video: "Modern Technology" by Andrew G, https://audiojungle.net/user/andrew_g  *Full transcript available on YouTube by clicking the “Show transcript” button on the bottom right of the video.

Learn practical tips for the inpatient management of patients with sickle cell disease and vaso-occlusive crisis from guest, Dr. Yoo Mee Shin (Emory). We cover acute pain management including adjuvant therapies, IV fluids, oxygen therapy, the management of acute chest syndrome, and when to perform simple vs exchange transfusions. Key takeaways include the importance of early triage and analgesia, addressing misconceptions about opioid use disorder in patients with sickle cell disease, and recognizing complications of vaso-occlusive crises. Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments 00:00 Intro 01:27 Getting to know our guest 07:48 Case Presentation and Initial Management of Sickle Cell Disease (SCD) 13:46 Misconceptions about opioid use disorder and sickle cell 17:02 Management of Acute Pain in Sickle Cell Disease 25:46 Adjuvant therapy for pain 29:04 Transition to outpatient care 32:46 General admission orders for sickle cell 38:44 Management of Acute Chest Syndrome 42:01 Simple vs exchange transfusion 47:08 Transfusion in preoperative and pregnant patients 48:03 Transitions and follow-up care 49:35 Key takeaways and Outro Credits Written and Produced by:  Matthew Watto MD, FACP Cover Art & Infographic: Matthew Watto MD, FACP Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Emi Okamoto MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Yoo Mee Shin MD Sponsor: Green Chef Go to greenchef.com/60curb and use code 60curb to get 60% off, plus 20% off your next two months. Sponsor: NetSuite Download NetSuite's popular KPI Checklist, designed to give you consistently excellent performance -absolutely free, at NetSuite.com/CURBSIDERS

In this 270th episode I welcome Drs. Michael Douglas and Leonard Soloniuk to the show to discuss the use of dexmedetomidine in spinals, epidurals and nerve blocks. Our Sponsors:* Check out Magic Mind and use my code ACC20 for a great deal: https://www.magicmind.com/Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy